1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
PELL Bio-Med Technology Co Ltd

PELL Bio-Med Technology Co Ltd

TTWSE:6949
37.70
TWD
-1.40
(-3.58%)
2.85BMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.42
0.43
0.39
0.34
0.54
- -
Basic EPS, GAAP
-5.63
-5.82
-8.55
-6.83
-7.23
- -
Free Cash Flow per Basic Share
-3.65
-4.29
-4.21
-9.19
-8.68
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
3.9
13.9
20.31
20.24
23.99
39.24
Tangible Book Value per Share
3.88
13.86
20.27
20.21
23.94
38.93
Basic Weighted Avg Shares
34
40
47
57
59
341
Sales/Revenue/Turnover
14
17
18
20
31
- -
Operating Margin (%)
-1,402.03
-1,375.79
-2,280.52
-2,106.35
-1,487.24
- -
Depreciation Expense
30
31
46
47
47
- -
Net Income, GAAP
-189
-230
-399
-389
-424
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1,351.93
-1,341.32
-2,211.26
-1,983.67
-1,349.09
- -
Working Capital
88
668
1,038
836
1,022
2,107
LT Debt
125
173
147
137
109
101
Total Equity
225
815
1,181
1,286
1,694
2,822
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-44.87
-40.46
-33.14
-32.59
- -

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
128
130
130
LT Borrowings
- -
- -
- -
LT Finance Leases
109
109
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
59
65
66
Market Capitalization
1,015
1,820
2,855

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,331
2,495
2,339
Cash, Cash Equivalents & STI
1,311
2,449
2,269
Accounts Receivable, Net
5
6
8
Inventories
7
13
19
Total Current Liabilities
309
260
232
Payables & Accruals
- -
- -
- -
ST Debt
128
130
130
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
31.7%
Free Cash Flow
- -
- -
-2.9%
Net Income, GAAP
- -
- -
8.87%
Sales/Revenue/Turnover
- -
- -
60.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
5
5
5
20
2025
12
6
- -
6
31
2026
6
9
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.54
-1.76
-1.75
-0.09
-6.83
2025
-1.3
-1.33
- -
-0.13
-7.23
2026
-1.18
-1.36
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cheng Lung Lin
Full Time Employees
94
Sector
Health technology
Industry
Biotechnology
Address
No. 87, Xinhu 2nd Rd. Taipei TP Taiwan 114
IPO Date
Mar 8, 2024
Website
pellbmt.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Pell Bio-Med Technology Co., Ltd. (6949.TW) develops cell culture technologies and techniques for therapeutic applications in the biotechnology sector, focusing on immune cell therapies and regenerative medicine; its core products and services include good tissue practice (GTP) laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative treatments such as degenerative joint conditions and aesthetic tissue filling, cytokine-induced killer (CIK) cells and dendritic cell-CIK (DC-CIK) therapies against cancers, chimeric antigen receptor T-cell (CAR-T), CAR-NK, and CAR-γδT immunotherapies, along with gene-modified ADSC and pipeline candidates targeting B-cell non-Hodgkin lymphoma (B-NHL), ovarian cancer, multiple myeloma, and thyroid cancer. Founded in 2017 and headquartered at No. 87, Xinhu 2nd Road, 4th Floor, Neihu District, Taipei, Taiwan, the company operates primarily in Taiwan with clinical applications centered on autologous T-cell therapies and stem cell regeneration for oncology and orthopedic patients. In recent developments, Pell Bio-Med Technology completed its initial public offering (IPO) on the Taiwan Stock Exchange's Taiwan Innovation Board in March 2024, marking a significant capital-raising milestone to advance its CAR-T product PL001 for B-cell lymphoma and other immune genetic engineering programs; it continues to report quarterly earnings, with third quarter 2025 results showing ongoing R&D investments amid revenue growth to NT$26.58 million (TTM) while advancing non-genetically modified immune cell treatments.